Safety and tolerability of lipid-lowering drugs after heart transplantation: The heart transplant lipid registry

Heart transplantation is associated with a high incidence of hyperlipidemia, and accelerated coronary artery disease is responsible for much of the post-transplant long-term morbidity and mortality. A multicenter Heart Transplant Lipid Registry was started in 1995 to gather prospective data on the safety and efficacy of lipid-lowering drugs in patients following heart transplant. Data thus far suggest that lipid-lowering therapy with statins is safe, with few adverse events requiring a change or adjustment in dose. There are no data yet on the long-term effects of lipid-lowering drugs on mortality from this registry.